Lexaria Bioscience Corp. Common Stock (LEXX)
Stock · NASDAQ · Health Care
$10.35as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$0.69461
Industry
Biotechnology: Pharmaceutical Preparations
About LEXX
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Website
- www.lexariabioscience.com/
Fundamentals
- Market cap
- $8.82M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-3.35
- Dividend yield
- —
- Beta
- 0.59
- Avg. volume
- —
52-week range
$4.21$23.25
How Lexaria Bioscience Corp. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Nov 28, 2025 · via SEC EDGAR / Finnhub
Lexaria Bioscience Corp. Common Stock Competitors
Chosen by industry and closest market cap.
- LEXXLexaria Bioscience Corp. Common Stock$10.35▼ 11.39%Market cap $8.82MP/E —$4.21$23.25
- XCURExicure Inc. Common Stock$1.34▼ 5.32%Market cap $8.60MP/E —$1.05$9.48
- QNRXQuoin Pharmaceuticals Ltd. American Depositary Shares$6.13▲ 18.91%Market cap $9.18MP/E —$3.25$41.8
- SNGXSoligenix Inc. Common Stock$0.38▲ 0.00%Market cap $8.24MP/E —$0.28$3.22
- GDTCCytoMed Therapeutics Limited Ordinary Shares$0.92▼ 4.17%Market cap $9.50MP/E —$0.6801$3.68
- APREAprea Therapeutics Inc. Common stock$0.8387▼ 2.48%Market cap $7.83MP/E —$0.548$1.69
- PCSAProcessa Pharmaceuticals Inc. Common Stock$2.07▼ 1.90%Market cap $7.65MP/E 3.31$1.67$14.24
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LEXX Lexaria Bioscience Corp. Common Stock | $8.82M | — | $10.35 | ▼ 11.39% | $4.21$23.25 |
| XCUR Exicure Inc. Common Stock | $8.60M | — | $1.34 | ▼ 5.32% | $1.05$9.48 |
| QNRX Quoin Pharmaceuticals Ltd. American Depositary Shares | $9.18M | — | $6.13 | ▲ 18.91% | $3.25$41.8 |
| SNGX Soligenix Inc. Common Stock | $8.24M | — | $0.38 | ▲ 0.00% | $0.28$3.22 |
| GDTC CytoMed Therapeutics Limited Ordinary Shares | $9.50M | — | $0.92 | ▼ 4.17% | $0.6801$3.68 |
| APRE Aprea Therapeutics Inc. Common stock | $7.83M | — | $0.8387 | ▼ 2.48% | $0.548$1.69 |
| PCSA Processa Pharmaceuticals Inc. Common Stock | $7.65M | 3.31 | $2.07 | ▼ 1.90% | $1.67$14.24 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Lexaria Bioscience Completes Blood Plasma Pharmacokinetic Bioanalysis Testing In Its 2026 Animal Study 2 Evaluating Oral Delivery Of 2 Next-Generation GLP-Drugs, Amycretin And Retatrutide, In A Total Of 18 Different Study Arms In Dogs Following Use Of Its DehydraTECH Drug Delivery Platformbenzinga · 8/24/2026
- Lexaria Bioscience Completes Blood Plasma Pharmacokinetic Bioanalysis Testing In Its 2026 Animal Study 2 Evaluating Oral Delivery Of 2 Next-Generation GLP-Drugs, Amycretin And Retatrutide, In A Total Of 18 Different Study Arms In Dogs Following Use Of Its DehydraTECH Drug Delivery PlatformBenzinga · 8/24/2026
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga · 8/17/2026
- Lexaria Bioscience Stock Rallies Thursday: What Investors Need to KnowBenzinga · 8/13/2026
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga · 8/13/2026
- Lexaria Bioscience Enters Material Transfer Agreement With Pegbio To Investigate LEXX's DehydraTECH Technology With A Proprietary Pegbio Molecule Under Development For The GLP-1 IndustryBenzinga · 8/13/2026
Insider Activity
Insider Actions →Acquired
0
Disposed
100.0K
- BUNKA CHRISTOPHER · March 17, 2026 · Gift100.0K
See the full, filterable feed with live charts on the MarketWall dashboard.